Optas LLC’s Biogen BIIB Stock Holding History

Optas LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$364K	Buy	1,685 +29	+2%	+$5.55K	0.05%	259
2026 Q1	$304K	Sell	1,656 -50	-3%	-$9.21K	0.05%	302
2025 Q4	$300K	Buy	1,706 +73	+4%	+$11.9K	0.05%	301
2025 Q3	$229K	Buy	1,633 +39	+2%	+$5.27K	0.04%	332
2025 Q2	$200K	Buy	+1,594	New	+$199K	0.04%	335
2021 Q4	–	Sell	-801	Closed	-$226K	–	154
2021 Q3	$226K	Buy	801 +4	+0.5%	+$1.31K	0.07%	129
2021 Q2	$277K	Buy	797 +1	+0.1%	+$303	0.08%	120
2021 Q1	$223K	Buy	+796	New	+$215K	0.07%	126
2020 Q4	–	Sell	-1,029	Closed	-$293K	–	146
2020 Q3	$293K	Buy	1,029 +93	+10%	+$25.9K	0.09%	132
2020 Q2	$250K	Sell	936 -778	-45%	-$234K	0.1%	105
2020 Q1	$542K	Sell	1,714 -39	-2%	-$11.8K	0.27%	51
2019 Q4	$521K	Buy	+1,753	New	+$486K	0.2%	75

Other funds holding BIIB

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ADEF

Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

NGM

North Growth Management Vancouver, British Columbia, Canada $780M AUM 102.77% 1-Year Est. Return

Optas LLC's BIIB Position: Q2 2026 in Review

Optas LLC increased its Biogen (BIIB) stake by 1.8% in Q2 2026, buying an estimated $5.55K and bringing the position to 1,685 shares worth $364K. The position accounts for 0.05% of the portfolio, ranked #259.

Optas LLC first reported a position in BIIB in Q4 2019 and has held it in 12 quarters since. The position peaked at $542K in Q1 2020. 241 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Optas LLC held 1,685 shares of Biogen worth $364K as of Q2 2026.
Optas LLC bought 29 Biogen shares in Q2 2026, an estimated $5.55K.
Biogen made up 0.05% of Optas LLC's portfolio in Q2 2026, its #259 holding.
Optas LLC first reported a position in Biogen in Q4 2019 and has held it in 12 quarters since.
Optas LLC's Biogen position peaked at $542K in Q1 2020.
241 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Optas LLC's 13F filing for Q2 2026, filed 21 Jul 2026.